Articles related to CONTROLLED MEDICINES

The FDA’s guidance on psychedelic medicine is a landmark in mental health treatment. With the potential to treat PTSD, addiction, and treatment-resistant depression, psychedelics could heighten the field. However, the guidance also highlights the need for rigorous study of these substances, particularly regarding their subjective effects and the role of psychological support.

The FDA’s recent warning about compounded ketamine products underscores the need for rigorous clinical studies to investigate ketamine’s benefit-risk profile and safe-use conditions in the treatment of psychiatric disorders.

Despite the potential benefits of ketamine in treating a range of neurological and psychiatric disorders, the FDA has issued warnings about the potential risks associated with its use, emphasizing the need for careful prescription and clinical oversight.

The DEA and HHS have extended telehealth prescribing flexibilities through December 31, 2024. This critical service allows for continued prescribing of controlled medications via virtual practice, addressing a significant need for many patients with mental health conditions and substance use disorders.

Stay abreast of the latest developments in patient care. Learn more about the FDA’s recent warning on the potential risks associated with compounded ketamine products used for treating psychiatric disorders.

The ASHP’s newly revised guidelines offer actionable steps for community pharmacies to combat controlled substance diversion, addressing both patient safety and regulatory compliance.